Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in High-Risk or Relapsed/Refractory Multiple Myeloma
NCT00112879Phase 2Withdrawn
- Sponsor
- Cleveland Clinic
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide, ascorbic acid, dexamethasone, thalidomide in multiple myeloma (MM), sponsored by Cleveland Clinic. Status: withdrawn.
02
Drugs
arsenic trioxideascorbic aciddexamethasonethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00112879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112879.